Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Revenue: US$2.77b (up 12% from 3Q 2023). Net income: US$1.05b (up 1.0% from 3Q 2023). Profit margin: 38% (down from 42% in 3Q 2023). EPS: US$4.05 (up from US$4.01 in 3Q 2023). Revenue exceeded ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Vertex Pharmaceuticals DRC stock. Vertex Pharma to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective ...

Vertex Pharma has teamed up with Orum Therapeutics ... including Vertex's CRISPR Therapeutics-partnered Casgevy (exagamglogene autotemcel), which became the first based on the CRISPR/Cas9 gene ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...